See also this year's filing and all EDGAR filings for this company.
PDF Report 0001503518_2012_21st_Century_Oncology_Holdings_Inc.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | No stock price available | subcommand.plot | {} |
| warning | Missing logo | subcommand.report | {} |
| warning | Ignoring company because Assets is zero | pre-agg | {'balance_sheet': {'company_id': '0001503518', 'Assets': 0, 'AssetsCurrent': 0, 'AssetsNonCurrent': 0, 'ComprehensiveNetIncome': -161740000, 'CostOfGoodsAndServicesSold': 0, 'DepreciationDepletionAndAmortization': 0, 'Expenses': 0, 'GeneralAndAdministrativeExpense': 0, 'GoodwillImpairmentLoss': 0, 'IntangibleAssets': 0, 'LaborExpense': 0, 'Liabilities': 892466000, 'LiabilitiesAndStockholdersEquity': 922301000, 'LiabilitiesCurrent': 0, 'LongTermLiabilities': 0, 'NetIncome': -151129000, 'OperatingCostsAndExpenses': 0, 'PropertyPlantAndEquipment': 0, 'RedeemableEquity': 11368000, 'ResearchAndDevelopmentExpense': 0, 'Revenues': 0, 'SellingAndMarketingExpense': 0, 'remainder_Assets': 0, 'remainder_ComprehensiveNetIncome': -10611000, 'remainder_Expenses': 0, 'remainder_Liabilities': 892466000, 'remainder_NetIncome': 0, 'remainder_Revenues': 0, 'remainder_StockholdersEquity': 18467000, 'obs_EconomicCapitalRatio': nan}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('EntityCommonStockSharesOutstanding')"} |
Graph
Absolute values for 0001503518, 21st Century Oncology Holdings Inc
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 598,940,000 |
| 1 | AssetsNonCurrent | 33,218,000 |
| 2 | AssetsCurrent | 116,304,000 |
| 3 | PropertyPlantAndEquipment | 236,411,000 |
| 4 | remainder_Assets | 13,719,000 |
| 5 | LongTermLiabilities | 687,747,000 |
| 6 | LiabilitiesCurrent | 96,375,000 |
| 7 | remainder_Liabilities | 24,448,000 |
| 8 | LaborExpense | 326,782,000 |
| 9 | CostOfGoodsAndServicesSold | 0 |
| 10 | GeneralAndAdministrativeExpense | 81,688,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 33,992,000 |
| 13 | DepreciationDepletionAndAmortization | 54,084,000 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 0 |
| 16 | remainder_Expenses | 498,054,000 |
| 17 | remainder_Revenues | 0 |
| 18 | remainder_NetIncome | 644,717,000 |
| 19 | remainder_ComprehensiveNetIncome | -5,395,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 998,592,000 |
| 1 | Liabilities | 808,570,000 |
| 2 | Expenses | 994,600,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 190,022,000 |
| 5 | NetIncome | -349,883,000 |
| 6 | ComprehensiveNetIncome | -355,278,000 |
| 7 | BaseVar | 1,725,937,000 |
| 8 | EconomicCapitalRatio | 0.191 |
Edgar->Model Mapping
Feature Distribution
